Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Islet Transplantation in Type 1 Diabetics Using the Edmonton Protocol of Steroid Free Immunosuppression
This study is ongoing, but not recruiting participants.
Sponsors and Collaborators: Emory University
Juvenile Diabetes Research Foundation
Information provided by: Emory University
ClinicalTrials.gov Identifier: NCT00133809
  Purpose

This trial will study the ability of islet transplantation to restore glycemic control and achieve insulin independence in type 1 diabetic subjects with life-threatening hypoglycemia and unawareness, or recurrent hyperglycemia with ketoacidosis.


Condition Intervention Phase
Diabetes Mellitus, Type 1
Procedure: Human Islet Transplantation
Phase II

MedlinePlus related topics: Diabetes Diabetes Type 1 Islet Cell Transplantation
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study
Official Title: Islet Transplantation in Type 1 Diabetes Using the Edmonton Protocol of Steroid Free Immunosuppression

Further study details as provided by Emory University:

Estimated Enrollment: 20
Study Start Date: July 2002
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 1 diabetes mellitus diagnosed > 5 years previously
  • Body mass index less than or equal to 26
  • 18 to 65 years of age
  • Compliance with an optimized diabetic management plan as assessed by an Emory University endocrinologist
  • Checking and recording blood sugars at least 3 times per day
  • Intensive insulin therapy (injecting insulin at least 3 times a day or using an insulin pump)
  • Severe hypoglycemia and/or hyperglycemia. Severe hypoglycemia is defined by: episodes requiring assistance by others and/or hypoglycemic unawareness (the inability to recognize blood glucose < 54 mg/dL). Severe hyperglycemia is defined by: two episodes of ketoacidosis requiring hospitalization within the past year.

Exclusion Criteria:

  • Renal dysfunction
  • Severe co-existing cardiac disease, characterized by any one of these conditions: recent myocardial infarction (within past six months); angiographic evidence of non-correctable coronary artery disease; or evidence of ischemia on a dobutamine stress echocardiogram.
  • Current bacterial or fungal infection
  • Macroproteinuria
  • Baseline hemoglobin < 11.4 gm/dL in women; < 12.9 gm/dL in men.
  • Hyperlipidemia
  • Positive tests for human immunodeficiency virus (HIV), or hepatitis B or C
  • Negative antibody test for varicella zoster virus (subjects may be reconsidered if they receive the vaccination and convert to a positive antibody)
  • History of malignancy (except squamous or basal cell skin carcinoma)
  • Previous/concurrent organ transplantation
  • Presence of HLA panel reactive antibodies > 20%
  • Active peptic ulcer disease
  • Evidence of gallbladder disease including cholecystitis and cholelithiasis
  • Evidence of liver disease including hepatic neoplasm, portal hypertension, or persistently abnormal liver function tests.
  • Persistent coagulopathy or current use of anticoagulants (not including aspirin)
  • Sickle cell anemia
  • Positive pregnancy test, intent for future pregnancy, failure to follow effective contraceptive measures, or presently breastfeeding
  • Active alcohol or substance abuse. This includes smoking (must be abstinent for six months). Active alcohol abuse should be considered using the current National Institute on Alcohol Abuse and Alcoholism (NIAAA) definitions.
  • Psychiatric disorder making the subject not a suitable candidate for transplantation
  • Current use of systemic steroid medications
  • Evidence of insulin resistance (insulin requirement > 1.2 units/kg/day)
  • Inability to provide informed consent
  • Any condition or any circumstance that makes it unsafe to undergo an islet transplant
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00133809

Locations
United States, Georgia
The Emory Transplant Center
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Juvenile Diabetes Research Foundation
Investigators
Principal Investigator: Christian P Larsen, MD PhD Emory University
Principal Investigator: Thomas Pearson, MD PhD Emory University
  More Information

Juvenile Diabetes Research Foundation, non-profit organization, sponsor of this study  This link exits the ClinicalTrials.gov site
Emory Transplant Center website  This link exits the ClinicalTrials.gov site

Study ID Numbers: 10402
Study First Received: August 22, 2005
Last Updated: October 25, 2005
ClinicalTrials.gov Identifier: NCT00133809  
Health Authority: United States: Food and Drug Administration

Keywords provided by Emory University:
Type 1 Diabetes
Islet Transplantation
Immunology

Study placed in the following topic categories:
Autoimmune Diseases
Metabolic Diseases
Diabetes Mellitus, Type 1
Diabetes Mellitus
Endocrine System Diseases
Endocrinopathy
Metabolic disorder
Glucose Metabolism Disorders

Additional relevant MeSH terms:
Immune System Diseases

ClinicalTrials.gov processed this record on January 14, 2009